A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

NCT ID: NCT02694770

Last Updated: 2016-04-25

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-31
• Study Completion Date: 2018-02-28

Brief Summary

This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease

Detailed Description

This current Phase II trial is a randomized, open label, controlled, multiple dose, multi-centre study to study the clinical efficacy and safety of Neihulizumab vs "Conventional Treatment" to treat steroid-refractory acute graft-vs-host disease (sr-aGvHD) in patients undergoing allogeneic hematopoietic cell transplantation.

This study will enroll a minimum of 90 patients, approximately 60 in Neihulizumab treatment arm and 30 in Conventional treatment control arm.

The primary objectives is to evaluate the efficacy of Neihulizumab treatment in patients with steroid-refractory acute GvHD compared to "conventional treatment." The secondary objectives are to investigate safety, pharmacokinetics, and immunogenicity of Neihulizumab administration in subjects with steroid-refractory acute GvHD.

For safety evaluation, the parameters to be assessed are adverse events (AEs), discontinuation of therapy due to AEs, safety laboratory analysis, ECG, vital signs, physical examination, and immunogenicity.

Conditions

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Neihulizumab

Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.

Group Type: EXPERIMENTAL

Neihulizumab Treatment

Intervention Type: BIOLOGICAL

Monoclonal antibody

"Conventional Treatment"

Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.

Group Type: ACTIVE_COMPARATOR

Conventional Treatment

Intervention Type: BIOLOGICAL

2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.

Interventions

Neihulizumab Treatment

Monoclonal antibody

Intervention Type: BIOLOGICAL

Conventional Treatment

2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.

Intervention Type: BIOLOGICAL

Other Intervention Names

AbGn-168H

Eligibility Criteria

Inclusion Criteria

1. Patient must be ≥18years of age, males or females;

2. Patient must have been recipients of a single allogeneic HCT; bone marrow, peripheral blood and/or umbilical cord blood recipients are allowed

3. Patients must have aGvHD without feature of classic chronic GvHD or overlap GvHD;

4. Patients must have received no prior treatment for aGvHD other than steroids;

5. Patients must have biopsy proven grade II to IV aGvHD progressing after at least 3 days, non-improving grade III to IV aGvHD persistent after at least 7 days, or non-improving grade II aGvHD persistent after at least 14 days of methylprednisolone 2mg/kg/day or equivalent; Patients with initial response but have flare of aGvHD within 14 days with methylprednisolone > 0.5 mg/kg/day or equivalent are also eligible;

6. Patient must have an ANC of > 500/mm3 and no evidence of HCT graft failure or multi-organ failure;

7. Patient must have Karnofsky Performance Status (KPS) ≥50%;

8. Patient must give informed consent and sign an approved consent form prior to any study procedures;

9. Females of childbearing potential must have a negative pregnancy test result prior to enrollment. Males and females of childbearing potential must agree to use a highly effective method of birth control during the study.

Exclusion Criteria

1. Uncontrolled infections not responsive to antimicrobial therapy or requiring intensive critical care or vasopressors;

2. Evidence of end-organ infection due to CMV;

3. HIV infection or a known HIV-related malignancy (NOTE: patients positive for hepatitis B or hepatitis C are not excluded, and may be evaluated on a case by case basis).

4. Tuberculosis, history of tuberculosis or a known positive Quantiferon test for tuberculosis

5. Donor lymphocyte infusion for residual or relapsed disease or mixed chimerism. DLI as part of the planned HCT protocol are allowed

6. Relapsed disease after transplant or progressive malignant disease, including post-transplant lymphoproliferative disease; any secondary malignancy diagnosed since HCT

7. Renal failure requiring hemodialysis

8. Need ICU care, with life expectancy of less than 28 days, with ongoing or unresolved veno-occlusive disease, with unstable hemodynamics, with evidence of current or previous clinically significant disease, medical condition or finding of the medical examination (including vital signs and ECG), that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data

9. History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients

10. Pregnant or nursing

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AbGenomics B.V Taiwan Branch

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shih-Yao Lin, MD, PhD

Role: STUDY_CHAIR

AbGenomics B.V.

Paul Martin (Lead), MD

Role: PRINCIPAL_INVESTIGATOR

Fred Hutchinson Cancer Center

Marco Mielcarek (Co-Lead), MD

Role: PRINCIPAL_INVESTIGATOR

Fred Hutchinson Cancer Center

Amin Alousi (Co-Lead), MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

MD Anderson Cancer Center

Houston, Texas, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Countries

United States

Other Identifiers

2015.011.01

Identifier Type: -

Identifier Source: org_study_id